Avalyn Pharma to Present Clinical Trial Insights and Drug Modeling Data at ERS 2026
Event summary
- Avalyn Pharma will present two posters at ERS International Congress 2026 in Barcelona, September 5-9.
- Posters cover patient perspectives on IPF trials and in silico modeling of nebulized pirfenidone (AP01).
- Presentations scheduled for September 7, with one session at 8:00 a.m. GMT and another at 12:30 p.m. GMT.
- AP01 is in Phase 2b trial (MIST) for progressive pulmonary fibrosis, with AP02 and AP03 in development.
The big picture
Avalyn's ERS presentations highlight its focus on inhaled antifibrotic therapies, a niche with growing interest as pulmonary fibrosis treatments shift toward lung-targeted delivery to reduce systemic side effects. The company's proprietary drug-device approach positions it in direct competition with established oral therapies from Roche (nintedanib) and Genentech (pirfenidone), where clinical differentiation will be key. Success in Phase 2b trials could validate Avalyn's platform and attract partnerships or acquisitions in the rare respiratory disease space.
What we're watching
- Clinical Validation
- Whether AP01's Phase 2b trial (MIST) will demonstrate superior lung-targeted efficacy over oral formulations.
- Regulatory Pathway
- The pace at which Avalyn can secure approvals for its inhaled combination therapy (AP03).
- Competitive Positioning
- How patient preference data from ERS 2026 will shape Avalyn's trial recruitment strategies.